{
  "symbol": "AMGN",
  "year": 2022,
  "period": "Q1",
  "curated_text": "Symbol: AMGN. Year: 2022. Period: Q1. ReportType: Q10. Section: Competition and Market Position. This section discusses competitors, market dynamics, and regulatory landscape.  Competitors mentioned: Authority, the Condensed Consolidated Balance Sheets, ROW, ROW Total U.S. ROW Total, Otezla, Bergamo, Company. Context excerpt: petition Authority. See Note 14, Subsequent events. As of September 30, 2022, held-for-sale assets and liabilities of $ 94 million and $ 18 million were included in Other current assets and Accrued liabilities, respectively, in the Condensed Consolidated Balance Sheets. During the nine months ended September 30, 2022, we recognized a loss of $ 565 million recorded in Other operating expenses in the Condensed Consolidated Statements of Income, primarily due to the impact of the cumulative foreign currency translation loss, with valuation allowances to Other current assets and Accrued liabilities in the Condensed Consolidated Balance Sheets. 9 3. Revenues We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers\u2019 locations, are presented below. The majority of ROW revenues r",
  "competition_summary": [
    {
      "competitor": "Authority",
      "mentions": 1,
      "context": "petition Authority. See Note 14, Subsequent events. As of September 30, 2022, held-for-sale assets and liabilities of $ 94 million and $ 18 million were included in Other current assets and Accrued liabilities, respectively, in the Condensed Consolidated Balance Sheets. During the nine months ended September 30, 2022, we recognized a loss of $ 565 million recorded in Other operating expenses in the Condensed Consolidated Statements of Income, primarily due to the impact of the cumulative foreign"
    },
    {
      "competitor": "the Condensed Consolidated Balance Sheets",
      "mentions": 2,
      "context": "petition Authority. See Note 14, Subsequent events. As of September 30, 2022, held-for-sale assets and liabilities of $ 94 million and $ 18 million were included in Other current assets and Accrued liabilities, respectively, in the Condensed Consolidated Balance Sheets. During the nine months ended September 30, 2022, we recognized a loss of $ 565 million recorded in Other operating expenses in the Condensed Consolidated Statements of Income, primarily due to the impact of the cumulative foreign"
    },
    {
      "competitor": "ROW",
      "mentions": 1,
      "context": "petition Authority. See Note 14, Subsequent events. As of September 30, 2022, held-for-sale assets and liabilities of $ 94 million and $ 18 million were included in Other current assets and Accrued liabilities, respectively, in the Condensed Consolidated Balance Sheets. During the nine months ended September 30, 2022, we recognized a loss of $ 565 million recorded in Other operating expenses in the Condensed Consolidated Statements of Income, primarily due to the impact of the cumulative foreign"
    },
    {
      "competitor": "ROW Total U.S. ROW Total",
      "mentions": 2,
      "context": "petition Authority. See Note 14, Subsequent events. As of September 30, 2022, held-for-sale assets and liabilities of $ 94 million and $ 18 million were included in Other current assets and Accrued liabilities, respectively, in the Condensed Consolidated Balance Sheets. During the nine months ended September 30, 2022, we recognized a loss of $ 565 million recorded in Other operating expenses in the Condensed Consolidated Statements of Income, primarily due to the impact of the cumulative foreign"
    },
    {
      "competitor": "Otezla",
      "mentions": 2,
      "context": "petition Authority. See Note 14, Subsequent events. As of September 30, 2022, held-for-sale assets and liabilities of $ 94 million and $ 18 million were included in Other current assets and Accrued liabilities, respectively, in the Condensed Consolidated Balance Sheets. During the nine months ended September 30, 2022, we recognized a loss of $ 565 million recorded in Other operating expenses in the Condensed Consolidated Statements of Income, primarily due to the impact of the cumulative foreign"
    },
    {
      "competitor": "Bergamo",
      "mentions": 1,
      "context": "petition Authority. See Note 14, Subsequent events. As of September 30, 2022, held-for-sale assets and liabilities of $ 94 million and $ 18 million were included in Other current assets and Accrued liabilities, respectively, in the Condensed Consolidated Balance Sheets. During the nine months ended September 30, 2022, we recognized a loss of $ 565 million recorded in Other operating expenses in the Condensed Consolidated Statements of Income, primarily due to the impact of the cumulative foreign"
    },
    {
      "competitor": "Company",
      "mentions": 2,
      "context": "petition Authority. See Note 14, Subsequent events. As of September 30, 2022, held-for-sale assets and liabilities of $ 94 million and $ 18 million were included in Other current assets and Accrued liabilities, respectively, in the Condensed Consolidated Balance Sheets. During the nine months ended September 30, 2022, we recognized a loss of $ 565 million recorded in Other operating expenses in the Condensed Consolidated Statements of Income, primarily due to the impact of the cumulative foreign"
    }
  ]
}